{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:26:30Z","timestamp":1778275590999,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40487-022-00208-1","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T15:02:50Z","timestamp":1663858970000},"page":"463-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02730104","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Scott","family":"Paulson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan","family":"Aranha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Scales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"10","key":"208_CR1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"7","key":"208_CR2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(7):839\u201368.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"208_CR3","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1530\/ERC-12-0024","volume":"19","author":"A Frilling","year":"2012","unstructured":"Frilling A, Akerstr\u00f6m G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr-Relat Cancer. 2012;19(5):R163\u201385.","journal-title":"Endocr-Relat Cancer"},{"issue":"12","key":"208_CR4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2967\/jnumed.116.179234","volume":"57","author":"CM Deroose","year":"2016","unstructured":"Deroose CM, Hindi\u00e9 E, Kebebew E, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57(12):1949\u201356.","journal-title":"J Nucl Med"},{"issue":"1","key":"208_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/gs.2017.10.08","volume":"7","author":"K \u00d6berg","year":"2018","unstructured":"\u00d6berg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg. 2018;7(1):20\u20137.","journal-title":"Gland Surg"},{"key":"208_CR6","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. 2015."},{"issue":"9","key":"208_CR7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930\u20136.","journal-title":"Oncologist"},{"issue":"5","key":"208_CR8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MPA.0000000000000818","volume":"46","author":"EM Wolin","year":"2017","unstructured":"Wolin EM, Leyden J, Goldstein G, Kolarova T, Hollander R, Warner RRP. Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas. 2017;46(5):639\u201347.","journal-title":"Pancreas"},{"issue":"4","key":"208_CR9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2214\/AJR.12.10240","volume":"201","author":"KW Kim","year":"2013","unstructured":"Kim KW, Krajewski KM, Nishino M, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol. 2013;201(4):811\u201324.","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"208_CR10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia"},{"issue":"10","key":"208_CR11","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1503\/cmaj.160771","volume":"189","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017;189(10):E398-e404.","journal-title":"CMAJ"},{"issue":"1","key":"208_CR12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12885-018-5057-3","volume":"18","author":"R Basuroy","year":"2018","unstructured":"Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018;18(1):1122.","journal-title":"BMC Cancer"},{"issue":"9","key":"208_CR13","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794\u2013803.","journal-title":"Ann Oncol"},{"key":"208_CR14","volume-title":"Highlights of US prescribing information: Somatuline Depot (lanreotide) injection, for subcutaneous use","author":"Ipsen Biopharmaceuticals Inc","year":"2019","unstructured":"Ipsen Biopharmaceuticals Inc. Highlights of US prescribing information: Somatuline Depot (lanreotide) injection, for subcutaneous use. Cambridge: Ipsen Biopharmaceuticals Inc; 2019."},{"issue":"3","key":"208_CR15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"key":"208_CR16","unstructured":"FDA. Framework for FDA's Real-World Evidence Program. 2018. Available at: https:\/\/www.fda.gov\/media\/120060\/download."},{"issue":"10","key":"208_CR17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1634\/theoncologist.2018-0798","volume":"24","author":"AJ Klink","year":"2019","unstructured":"Klink AJ, Feinberg B, Yu HT, et al. Patterns of care among real-world patients with metastatic neuroendocrine tumors. Oncologist. 2019;24(10):1331\u20139.","journal-title":"Oncologist"},{"issue":"9","key":"208_CR18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MPA.0000000000001403","volume":"48","author":"L Huynh","year":"2019","unstructured":"Huynh L, Cai B, Cheng M, et al. Analysis of real-world treatment patterns, healthcare resource utilization, and costs between octreotide and lanreotide among patients with neuroendocrine tumors. Pancreas. 2019;48(9):1126\u201335.","journal-title":"Pancreas"},{"issue":"1","key":"208_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers M-P, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"208_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.surg.2017.01.019","volume":"162","author":"E Jun","year":"2017","unstructured":"Jun E, Kim SC, Song KB, et al. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: a prospective observational study from a single institute. Surgery. 2017;162(1):120\u201330.","journal-title":"Surgery"},{"issue":"4","key":"208_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000497330","volume":"108","author":"JK Ramage","year":"2019","unstructured":"Ramage JK, Punia P, Faluyi O, et al. Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE Study (UK Phase IV Trial). Neuroendocrinology. 2019;108(4):317\u201327.","journal-title":"Neuroendocrinology"},{"key":"208_CR22","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2010."},{"key":"208_CR23","unstructured":"SAS\/ACCESS\u00ae 9.4 Interface to ADABAS: Reference. Cary: SAS Institute Inc; 2013."},{"issue":"2","key":"208_CR24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MEG.0b013e328359d1a6","volume":"25","author":"M Palazzo","year":"2013","unstructured":"Palazzo M, Lombard-Bohas C, Cadiot G, et al. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. Eur J Gastroenterol Hepatol. 2013;25(2):232\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"208_CR25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","volume":"34","author":"MS Khan","year":"2011","unstructured":"Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34(2):235\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"208_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/clinem\/dgz007","volume":"105","author":"A Faggiano","year":"2020","unstructured":"Faggiano A, Modica R, Lo Calzo F, et al. Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J Clin Endocrinol Metab. 2020;105(1):78\u201384.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"208_CR27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12020-019-01894-0","volume":"66","author":"A Faggiano","year":"2019","unstructured":"Faggiano A, Di Maio S, Mocerino C, et al. Therapeutic sequences in patients with grade 1\u20132 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019;66(2):417\u201324.","journal-title":"Endocrine"},{"issue":"2","key":"208_CR28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","volume":"71","author":"ME Caplin","year":"2021","unstructured":"Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502\u201313.","journal-title":"Endocrine"},{"key":"208_CR29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"Pavel M, \u0106wik\u0142a JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403\u201314.","journal-title":"Eur J Cancer"},{"issue":"2","key":"208_CR30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"7","key":"208_CR31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","volume":"29","author":"MH Kulke","year":"2011","unstructured":"Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29(7):934\u201343.","journal-title":"J Clin Oncol"},{"issue":"28","key":"208_CR32","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"6","key":"208_CR33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"208_CR34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","volume":"28","author":"S Faivre","year":"2017","unstructured":"Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339\u201343.","journal-title":"Ann Oncol"},{"issue":"9","key":"208_CR35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380.","journal-title":"Endocr Pract"},{"issue":"3","key":"208_CR36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1634\/theoncologist.2016-0305","volume":"22","author":"M Michael","year":"2017","unstructured":"Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The antiproliferative role of lanreotide in controlling growth of neuroendocrine tumors: a systematic review. Oncologist. 2017;22(3):272\u201385.","journal-title":"Oncologist"},{"issue":"8","key":"208_CR37","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","volume":"37","author":"T Aparicio","year":"2001","unstructured":"Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001;37(8):1014\u20139.","journal-title":"Eur J Cancer"},{"key":"208_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00025","volume":"3","author":"JR Adams","year":"2019","unstructured":"Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living with neuroendocrine tumors: assessment of quality of life through a mobile application. JCO Clin Cancer Inform. 2019;3:1\u201310.","journal-title":"JCO Clin Cancer Inform"},{"key":"208_CR39","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1007\/s00520-022-07054-x","volume":"30","author":"C Seo","year":"2020","unstructured":"Seo C, Horodniceanu E, Shah R, et al. Patient experience with somatostatin analog treatments for neuroendocrine tumors: insight from qualitative interviews. Support Care Cancer. 2020;30:6307\u201316.","journal-title":"Support Care Cancer"},{"issue":"47","key":"208_CR40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013390","volume":"97","author":"DM Halperin","year":"2018","unstructured":"Halperin DM, Huynh L, Beaumont JL, et al. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: a survey study. Medicine (Baltimore). 2018;97(47): e13390.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"208_CR41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1177\/1078155219839458","volume":"25","author":"P Ryan","year":"2019","unstructured":"Ryan P, McBride A, Ray D, et al. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: an observational time and motion analysis. J Oncol Pharm Pract. 2019;25(6):1425\u201333.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"208_CR42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","volume":"48","author":"P Ruszniewski","year":"2016","unstructured":"Ruszniewski P, Valle JW, Lombard-Bohas C, et al. Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48(5):552\u20138.","journal-title":"Dig Liver Dis"},{"key":"208_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"CD Barbosa","year":"2012","unstructured":"Barbosa CD, Balp M-M, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"208_CR44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304\u201314.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"208_CR45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"1","key":"208_CR46","first-page":"29","volume":"26","author":"M D\u00edez","year":"2013","unstructured":"D\u00edez M, Teul\u00e9 A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol. 2013;26(1):29\u201336.","journal-title":"Ann Gastroenterol"},{"issue":"Suppl 1","key":"208_CR47","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1007\/s00259-011-1989-4","volume":"39","author":"V Ambrosini","year":"2012","unstructured":"Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S52-60.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7\u20138","key":"208_CR48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000504370","volume":"110","author":"AM Berner","year":"2020","unstructured":"Berner AM, Pipinikas C, Ryan A, et al. Diagnostic approaches to neuroendocrine neoplasms of unknown primary site. Neuroendocrinology. 2020;110(7\u20138):563\u201373.","journal-title":"Neuroendocrinology"},{"key":"208_CR49","doi-asserted-by":"crossref","first-page":"3519247","DOI":"10.1155\/2018\/3519247","volume":"2018","author":"A Chauhan","year":"2018","unstructured":"Chauhan A, Farooqui Z, Murray LA, et al. Capecitabine and temozolomide in neuroendocrine tumor of unknown primary. J Oncol. 2018;2018:3519247.","journal-title":"J Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-022-00208-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-022-00208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T07:46:01Z","timestamp":1669103161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-022-00208-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["208"],"URL":"https:\/\/doi.org\/10.1007\/s40487-022-00208-1","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}